Decrease of natural killer cell activity and monokine production in peripheral blood of patients treated with recombinant tumor necrosis factor

URN to cite this document:: urn:nbn:de:bvb:355-epub-211804
DOI to cite this document:: 10.5283/epub.21180

Kist, A. ; Ho, A. D. ; Räth, U. ; Wiedenmann, B. ; Bauer, A. ; Schlick, E. ; Kirchner, H. ; Männel, Daniela N.

Preview

PDF
(996kB)

Date of publication of this fulltext: 20 Jun 2011 06:14

Alternative links to fulltext:Pubmed

Details

Preview

Export bibliographical data

Abstract

Tumor necrosis factor (TNF), a protein predominantly produced by activated macrophages/monocytes, is presently available in recombinant, purified form for clinical trials. Intensive studies in many laboratories have shown that besides the tumorcytotoxic effects, TNF acts on a large array of different cells and has potent immunomodulatory activities. In a clinical phase I study, some immunologic ...